Skip to content

effect of the combination of green lipped mussel, curcumin and ribus nigrum (supplement Synofit) on quality of life and pain in patients with osteoarthritis of the knee

effect of the combination of green lipped mussel, curcumin and ribus nigrum (supplement Synofit) on quality of life and pain in patients with osteoarthritis of the knee - Effect of Synofit in patients with osteoarthritis of the knee

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON39393
Enrollment
62
Registered
2013-08-09
Start date
2013-10-15
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arthritis of the knee gonarthritis

Interventions

first 6 weeks of placebo or combination of green lipped mussel, curcumin and ribus nigrum (supplement Synofit) supplemantation after that a wash-out interval of 6 weeks followed by 6 weeks of either

Sponsors

Ziekenhuisvoorzieningen Gelderse Vallei
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - patients with clinical and radiological osteoarthritis of the knee (uni-and bilateral) - voluntary participation

Exclusion criteria

Exclusion criteria: - patients with arthritis of the knee with an operation indication - comborbidity: rheumatoid arthritis, polyarthritis - patient who use medication as: methotrexate and systemic corticosteroids - arthritis of the hip at the same side (referred pain) - patients who use analgetica stronger than NSAIDs (f.e. Tramadol, Opioids) - pregnancy - allergic or sensitivity for ingredients of Synofit - patient who use Synofit before

Design outcomes

Primary

MeasureTime frame
during the first consultation and at 6, 12 and 18 weeks, the pain scores by the VAS-scale and quality of life by the KOOS-score are taken. Another outcome is extra pain medication within one of the study periods of suppletion.

Secondary

MeasureTime frame
side-effects compliance

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)